ArticleInternational journal of oncology2024

HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.

Yang He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.